Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from InnoCare Pharma Ltd. ( (HK:9969) ) is now available.
InnoCare Pharma has granted 1.4 million restricted share units (RSUs), equivalent to about 0.08% of its issued share capital, to two employee participants under its 2023 Share Award Scheme, with a purchase price set well below the prevailing market prices of its Hong Kong and RMB shares. Of these, 800,000 RSUs will vest in four equal tranches over one to four years, while the remaining 600,000 RSUs are tied to performance-based vesting conditions linked to both corporate metrics such as operating revenue and the number of clinical trials, and individual performance evaluations, underscoring the company’s use of equity incentives to retain key staff, align employee interests with long-term commercialization and R&D goals, and potentially support its competitive positioning in the biopharma sector.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$23.60 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a Hong Kong–listed biopharmaceutical company focused on the research, development and commercialization of innovative therapies, with a business model that emphasizes advancing clinical trials and generating operating revenue from its drug portfolio in China and other key markets.
Average Trading Volume: 9,282,606
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.95B
See more data about 9969 stock on TipRanks’ Stock Analysis page.